Lung cancer trials in China

In China 1146 Also abroad 2733

1,146 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Neijiang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 2Taking people
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Where
Dongguan, Guangzhou, Jinan
Age
18 years and over
People
130 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00
Phase 1/2Taking people
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Where
Guangzhou, Harbin, Shanghai
Age
18 years and over
People
60 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07227025
Phase 2Taking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Beijing, Changchun, Nanjing, Shanghai, Tianjin, Zhangjiakou, Zhengzhou
Age
18 years and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
Phase 2Taking people
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Where
Beijing, Chengdu, Cheng Du Shi, Guangzhou, Jinan, Shanghai, Tianjin
Age
18 years and over
People
68 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07586202
No phaseTaking people
ePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis
Where
Hubei
Age
18 years and over
People
200
Run by
Qian Chu
See details and how to joinNCT07912190
Phase 1Not yet taking people in China
Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Changchun, Changsha, Fuzhou, Harbin, Nanchang, Shanghai, Taizhou
Age
18 years and over
People
270
Run by
Jiangsu Simcere Pharmaceutical Co., Ltd.
See details and how to joinNCT07912268
Phase 1/2Not yet taking people in China
Antigen-specific T Cells Against Lung Cancer
Where
Shenzhen
Age
18 years to 80 years
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03356808
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Qujing, Shanghai, Wuhan, Zhengzhou
Age
18 years and over
People
66 worldwide
Run by
Teligene US
See details and how to joinNCT06010329
Phase 1Taking people
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Where
Shanghai
Age
18 years to 75 years
People
115
Run by
Biokin (Shanghai) Biopharmaceutical Co., Ltd.
See details and how to joinNCT06505824
Phase 2/3Taking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Baoding, Beijing, Bengbu, Changchun, Changsha, Hangzhou, Jiamusi, Jinan, Kunming, Nanjing, Shanghai, Shantou, Suzhou, Wanzhou, Wuhan, Yangzhou, Zhejiang
Age
18 years and over
People
1,580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Beijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xiamen, Xinxiang, Yibin, Zhengzhou
Age
18 years and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Linyi, Nanchang, Nanjing, Ningbo, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
Phase 3Taking people
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi’an, Xinxiang, Xuzhou, Zhengzhou
Age
18 years and over
People
1,200 worldwide
Run by
Takeda
See details and how to joinNCT07217301 · EU 2026-525659-94-00
Phase 2Taking people
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Where
Shanghai
Age
18 years and over
People
36
Run by
Biokin (Shanghai) Biopharmaceutical Co., Ltd.
See details and how to joinNCT07654400
Phase 3Taking people
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC
Where
Guangzhou
Age
18 years and over
People
206
Run by
Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT07754123
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Liuzhou, Luzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Ürümqi, Wuhan, Xiamen, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 3Taking people
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
Where
Shanghai
Age
18 years and over
People
556
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07802821
No phaseTaking people
Exploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain Injury
Where
Guiyang
Age
18 years to 75 years
People
42
Run by
Guizhou Medical University
See details and how to joinNCT07905937
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linhai, Linyi, Nanchang, Nanjing, Nanning, Nantong, Nanyang, Ningbo, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Ürümqi, Wuhan, Xiamen, Xi'an, Zhanjiang, Zhengzhou
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 2Taking people
PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients
Where
Fuzhou
Age
18 years to 75 years
People
214
Run by
Fujian Medical University Union Hospital
See details and how to joinNCT05704166
Phase 3Taking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Huai'an, Nanchang, Shanghai, Taizhou, Ürümqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou
Age
18 years and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linhai, Linyi, Nanchang, Ningbo, Shanghai, Shenyang, Shenzhen, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Yangzhou, Yueyang, Zhengzhou
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Beijing, Changsha, Chengdu, Dongguan, Henan, Hubei, Shanghai, Shenyang, Wuhan, Xi'an, Xinxiang, Xuzhou
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 2Taking people
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
Where
Guangzhou
Age
18 years to 80 years
People
46
Run by
Zhujiang Hospital
See details and how to joinNCT07534033